<DOC>
	<DOCNO>NCT02485873</DOCNO>
	<brief_summary>To obtain good understand comparative effectiveness rivaroxaban vitamin K antagonist ( VKA ) stroke prevention patient non-valvular atrial fibrillation ( SPAF ) real-life set</brief_summary>
	<brief_title>Real-Life Evidence Stroke Prevention SPAF</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Age â‰¥18 year day first prescription study drug ( = index date ) study selection window Diagnosis NVAF start date study anytime 365 day date Availability followup least 180 day date first prescription study drug within selection window study ( exposure start date ) Evidence patient activity database 90 day date first prescription target drug within selection window . Patients valvular AF Prescriptions Oral Anticoagulants ( OACs ) : VKA , Dabigatran , Rivaroxaban index date Prescription one OAC index date switch another OAC followup period Prescriptions &lt; 15mg rivaroxaban index date followup period patient rivaroxaban cohort</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Non-valvular atrial fibrillation ( NVAF )</keyword>
	<keyword>Pevention</keyword>
	<keyword>Stroke</keyword>
</DOC>